CA2098773C - Recombinant coccidia and its use in a vaccine - Google Patents
Recombinant coccidia and its use in a vaccineInfo
- Publication number
- CA2098773C CA2098773C CA002098773A CA2098773A CA2098773C CA 2098773 C CA2098773 C CA 2098773C CA 002098773 A CA002098773 A CA 002098773A CA 2098773 A CA2098773 A CA 2098773A CA 2098773 C CA2098773 C CA 2098773C
- Authority
- CA
- Canada
- Prior art keywords
- dna
- coccidia
- recombinant
- donor
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000224483 Coccidia Species 0.000 title claims abstract description 60
- 229960005486 vaccine Drugs 0.000 title claims abstract description 36
- 241000894007 species Species 0.000 claims abstract description 42
- 208000003495 Coccidiosis Diseases 0.000 claims abstract description 20
- 206010023076 Isosporiasis Diseases 0.000 claims abstract description 20
- 230000036039 immunity Effects 0.000 claims abstract description 18
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 11
- 238000011081 inoculation Methods 0.000 claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims description 160
- 241000223932 Eimeria tenella Species 0.000 claims description 55
- 241000223931 Eimeria acervulina Species 0.000 claims description 36
- 241000223924 Eimeria Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 16
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 7
- 241000499566 Eimeria brunetti Species 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 241000223934 Eimeria maxima Species 0.000 claims description 5
- 241000499563 Eimeria necatrix Species 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 3
- 238000000520 microinjection Methods 0.000 claims description 3
- 108091035539 telomere Proteins 0.000 claims description 2
- 210000003411 telomere Anatomy 0.000 claims description 2
- 102000055501 telomere Human genes 0.000 claims description 2
- 210000003250 oocyst Anatomy 0.000 description 34
- 210000003046 sporozoite Anatomy 0.000 description 20
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 241000287828 Gallus gallus Species 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000011324 bead Substances 0.000 description 13
- 238000012546 transfer Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 241000271566 Aves Species 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 230000001165 anti-coccidial effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 7
- 229960005542 ethidium bromide Drugs 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 244000144992 flock Species 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229930191564 Monensin Natural products 0.000 description 5
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000002555 ionophore Substances 0.000 description 5
- 230000000236 ionophoric effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960005358 monensin Drugs 0.000 description 5
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 4
- 241000193464 Clostridium sp. Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 210000004507 artificial chromosome Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000007900 DNA-DNA hybridization Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124536 anticoccidial agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000005005 gametogony Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MOOFYEJFXBSZGE-QJUDHZBZSA-N 1,2-bis[(z)-(4-chlorophenyl)methylideneamino]guanidine Chemical compound C=1C=C(Cl)C=CC=1\C=N/N=C(/N)N\N=C/C1=CC=C(Cl)C=C1 MOOFYEJFXBSZGE-QJUDHZBZSA-N 0.000 description 1
- WINSLRIENGBHSH-ASZYJFLUSA-N 2-[(2r,3s,4s,5r,6s)-2,4-dihydroxy-6-[(1r)-1-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-[(2s,5s,6r)-5-methoxy-6-methyloxan-2-yl]oxyoxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspi Chemical compound O1[C@H](C)[C@@H](OC)CC[C@@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](O)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WINSLRIENGBHSH-ASZYJFLUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000289819 Eimeria adenoeides Species 0.000 description 1
- 241001327857 Eimeria gallopavonis Species 0.000 description 1
- 241001278028 Eimeria meleagrimitis Species 0.000 description 1
- 241000179199 Eimeria mitis Species 0.000 description 1
- 241000499544 Eimeria praecox Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 108020000949 Fungal DNA Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930182504 Lasalocid Natural products 0.000 description 1
- 101100390735 Mus musculus Figla gene Proteins 0.000 description 1
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 description 1
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Chemical group 0.000 description 1
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710152205 Sporozoite antigen Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960000731 clopidol Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 229960000320 lasalocid Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- -1 maduramaicin Chemical compound 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001851 narasin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940073485 nicarbazin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004591 robenidine Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000017259 schizogony Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960004388 semduramicin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- HODRFAVLXIFVTR-RKDXNWHRSA-N tevenel Chemical compound NS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 HODRFAVLXIFVTR-RKDXNWHRSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides for recombinant coccidia comprising a relatively non-pathogenic strain of coccidia to which has been introduced DNA from one or more other strains or species of coccidia. In an aspect of the invention, there is provided a recombinant coccidiosis vaccine comprising a relatively non-pathogenic strain of coccidia to which has been introduced sufficient DNA of one or more other strains or species of coccidia to produce immunity to the multiple species in a host through inoculation of the host by the recombinant species.
Description
RECOMBINANT COCCIDIA AND ITS USE IN A VACCINE
The present invention is directed to a recombinant coccidia in which the DNA of other strains or species of coccidia has been introduced into a relatively non-pathogenic strain of coccidia. The invention is also directed to a coccidiosis vaccine utilizing the recombinant coccidia to produce immunity to multiple species of coccidia in a host through inoculation of the host by the recombinant species.
BACK ,RO ND O mBE rpT~rFrlmTn~
Coccidiosis is an intestinal disease caused as a result of infection by coccidia, an obligate intercellular protozoa. As infections are transmitted by environmentally resistant oocysts released in the feces of infected animals and because livestock are often kept together in large numbers, coccidiosis has become an important disease of livestock throughout the world. In poultry, coccidiosis is the most frequently recorded disease which according to some estimates is responsible for losses i.n excess of $1 billion per year. Without adequate measures to control coccidiosis, the poultry industry could not continue to exist.
In poultr y, coccidiosis is a result of infection by coccidia of the Genera Eimer.ia. There are at present ~~9~'~'~~
The present invention is directed to a recombinant coccidia in which the DNA of other strains or species of coccidia has been introduced into a relatively non-pathogenic strain of coccidia. The invention is also directed to a coccidiosis vaccine utilizing the recombinant coccidia to produce immunity to multiple species of coccidia in a host through inoculation of the host by the recombinant species.
BACK ,RO ND O mBE rpT~rFrlmTn~
Coccidiosis is an intestinal disease caused as a result of infection by coccidia, an obligate intercellular protozoa. As infections are transmitted by environmentally resistant oocysts released in the feces of infected animals and because livestock are often kept together in large numbers, coccidiosis has become an important disease of livestock throughout the world. In poultry, coccidiosis is the most frequently recorded disease which according to some estimates is responsible for losses i.n excess of $1 billion per year. Without adequate measures to control coccidiosis, the poultry industry could not continue to exist.
In poultr y, coccidiosis is a result of infection by coccidia of the Genera Eimer.ia. There are at present ~~9~'~'~~
seven known species of Eimeria which infect chickens;
E.acervulina, E.brunetti, E.max_ima, E.mitis, E.neoatrix, E.praecox and E.tenella. E.tenella and E.necatrix are the most pathogenic followed by E.brunetti and E.maxima. In turkeys, there are also at present seven known species with E, adenoides considered the most pathogenic and E.
gallopavonis and E. meleagrimitis also considered important in terms of clinical disease. Eimerians are host specific in that those species which infect one species of host do not generally infect other hosts. Not only are the Eimerians host specific but they parisitize specific sites :rithin the host and specific cell types within a tissue or organ. In chicken, species of Eimeria parasitize and develop in different regions of the gut with E.acervulina occupying the most proximal region and E.tenella and E.brunetti the most distal regions. In addition, different stages of a single species can be specific to different regions of the intestine and different cell types within that region. In E.necatrix infections, for example, two generations of schizogony occur within crypt epithelial cells of the ileum but gametogony occurs in surface epithelial cells of the ceca.
Species of Eimeria generally develop in epithelial cells of endodermal origin, with the majority parasitizing epithelial cells of the intestinal mucosa.
Coccidiosis infection generally results in villus flattening or atrophy, crypt hyperplasia and decreases in villus/crypt ratios accompanied by varying degrees of malaise, diarrhea, maladsoption, and reduction in growth rate. Severe infections frequently lead to death.
As early as 1929 (Tyzzer, 1929), ~it was shown that immunity developed during a coccidial infection such that birds which recovered from such infections were generally immune to further infection. Studies have described the presence of numerous antigens in Eimeria species with different antigenic profiles associated with 2~~°'"~'~
E.acervulina, E.brunetti, E.max_ima, E.mitis, E.neoatrix, E.praecox and E.tenella. E.tenella and E.necatrix are the most pathogenic followed by E.brunetti and E.maxima. In turkeys, there are also at present seven known species with E, adenoides considered the most pathogenic and E.
gallopavonis and E. meleagrimitis also considered important in terms of clinical disease. Eimerians are host specific in that those species which infect one species of host do not generally infect other hosts. Not only are the Eimerians host specific but they parisitize specific sites :rithin the host and specific cell types within a tissue or organ. In chicken, species of Eimeria parasitize and develop in different regions of the gut with E.acervulina occupying the most proximal region and E.tenella and E.brunetti the most distal regions. In addition, different stages of a single species can be specific to different regions of the intestine and different cell types within that region. In E.necatrix infections, for example, two generations of schizogony occur within crypt epithelial cells of the ileum but gametogony occurs in surface epithelial cells of the ceca.
Species of Eimeria generally develop in epithelial cells of endodermal origin, with the majority parasitizing epithelial cells of the intestinal mucosa.
Coccidiosis infection generally results in villus flattening or atrophy, crypt hyperplasia and decreases in villus/crypt ratios accompanied by varying degrees of malaise, diarrhea, maladsoption, and reduction in growth rate. Severe infections frequently lead to death.
As early as 1929 (Tyzzer, 1929), ~it was shown that immunity developed during a coccidial infection such that birds which recovered from such infections were generally immune to further infection. Studies have described the presence of numerous antigens in Eimeria species with different antigenic profiles associated with 2~~°'"~'~
the different stages of the development of the Eimeria (Wisher 1986; Clarke et al, 1987; Jenkins et al, 1988;
hillehoj et al, 1988; Brothers et al, 1988, Profous-Juchelba et al, 1988, Castle et al, 1991). The life stage of Eimeria parasites is intricate consisting of several differing generations of asexual replication followed by the development of the sexual stacJes. These different life cycle stages differ in immunogenicity and antigenic composition (McDougall et al (1986)). Recent work has indicated that the gametogony stages are not as immunogenic as developing asexual forms of the parasite and more recent studies have indicated that of all the stages, the sporozoite, particularly in E.tenella, may be the major target for the development of the immune response in the host. The nature of the immune response in the host is generally a combination of antibody mediated and cell-mediated responses with T-cell dependent immunity being the prevalent mechanism of immunity to infection (For review see Rose chapter in Long (1990)).
Coccidiosis control is most commonly accomplished through the use of anti-coccidial drugs. The anti-coccidial drugs are mixed into the feed at low levels to be given continuously to the growing chickens for continuous prevention of coccidiosis. Amongst the anti-coccidial drugs most commonly used are the polyether ionophores with monensin being the most commonly used ionophore. Monensin is usually administered in the range of 60 to 90 rpm and is continually administered to the animal from birth up to slaughter although some producers continue the practice of weaning off the monensin for 5 to 7 days prior to slaughter. Other commonly utilized anti-coccidial drugs include salinomycin, lasalocid, narasin, maduramaicin, and semduramicin, nicarbazin. By far the most significant use of anti-coccidial drugs is in broiler chickens which is estimated to cost in excess of $350 million yearly.
hillehoj et al, 1988; Brothers et al, 1988, Profous-Juchelba et al, 1988, Castle et al, 1991). The life stage of Eimeria parasites is intricate consisting of several differing generations of asexual replication followed by the development of the sexual stacJes. These different life cycle stages differ in immunogenicity and antigenic composition (McDougall et al (1986)). Recent work has indicated that the gametogony stages are not as immunogenic as developing asexual forms of the parasite and more recent studies have indicated that of all the stages, the sporozoite, particularly in E.tenella, may be the major target for the development of the immune response in the host. The nature of the immune response in the host is generally a combination of antibody mediated and cell-mediated responses with T-cell dependent immunity being the prevalent mechanism of immunity to infection (For review see Rose chapter in Long (1990)).
Coccidiosis control is most commonly accomplished through the use of anti-coccidial drugs. The anti-coccidial drugs are mixed into the feed at low levels to be given continuously to the growing chickens for continuous prevention of coccidiosis. Amongst the anti-coccidial drugs most commonly used are the polyether ionophores with monensin being the most commonly used ionophore. Monensin is usually administered in the range of 60 to 90 rpm and is continually administered to the animal from birth up to slaughter although some producers continue the practice of weaning off the monensin for 5 to 7 days prior to slaughter. Other commonly utilized anti-coccidial drugs include salinomycin, lasalocid, narasin, maduramaicin, and semduramicin, nicarbazin. By far the most significant use of anti-coccidial drugs is in broiler chickens which is estimated to cost in excess of $350 million yearly.
The intensive use of the anti-coccidial drugs has lead to the emergence of coccidials with reduced sensitivity or drug resistance. When a coccidium becomes resistant to a drug there is usually a collateral resistance to other drugs of the same chemical class but not to unrelated drugs. Drug resistance has been found to be a genetic trait and tends to remain in a population for many years. Coccidia have more difficulty in becoming resistant to some drugs than in others. For example, resistance to halofuginone, clopidol, quinolones and robenidine has been found within a year of the use while resistance to monensin and other ionophores were slower to develop but in recent years the incidence of coccidial resistance to the ionophores has increased significantly (See McDougall chapter in Long,1990).
To attempt to prevent the development of drug resistance, alternate use of drugs has been proposed using programs such as shuttle and rotation programs. A shuttle program is practiced within the growout of a flock where one drug is used for the first three to four weeks and then another drug is used fox the remainder of the flock's life.
Generally, in this program, a strong drug is used initially in the starter feed followed by one of the ionophores such as monensin in the grower feed. A rotation program simply alternates the use of two or more drugs at various intervals between flocks such as over three to six month periods) The development of drug resistance has limited the effectiveness of anti-coccidials and it is likely that this development will intensify over the next few years.
To overcome this, considerable effort has been spent aimed at the development of vaccines which will provide~long term immunity to the animal without the necessity of utilizing anti-coccidial drugs.
To attempt to prevent the development of drug resistance, alternate use of drugs has been proposed using programs such as shuttle and rotation programs. A shuttle program is practiced within the growout of a flock where one drug is used for the first three to four weeks and then another drug is used fox the remainder of the flock's life.
Generally, in this program, a strong drug is used initially in the starter feed followed by one of the ionophores such as monensin in the grower feed. A rotation program simply alternates the use of two or more drugs at various intervals between flocks such as over three to six month periods) The development of drug resistance has limited the effectiveness of anti-coccidials and it is likely that this development will intensify over the next few years.
To overcome this, considerable effort has been spent aimed at the development of vaccines which will provide~long term immunity to the animal without the necessity of utilizing anti-coccidial drugs.
Owing to the intricacy of the life stages of the coccidia and the numerous antigens present with the different antigenic profiles associated with the different stages of development, the production of suitable vaccines has not proceeded as well as had been hoped. while there have been isolated -reports of immunization against a specific strain of coccidia through the use of isolated antigen (hurray et al, 1986), no one antigen or series of antigens has been developed which will provide protection against all species of coccidia which infect the animal.
Such protection has only been accomplished through the use of live vaccines which contain oocysts from all relevant species of coccidia. Examples of vaccines presently commercially available include: COCCIVAC and IMMUCOX, both live, virulent vaccines containing oocysts from the seven species of Eimeria that parasitize domestic fowl, and PARACOX, a live, attenuated vaccine.
The vaccines are generally administered either in one large dose within the first few days of life or through the use of smaller doses given singularly or at separate times over the first few weeks of life.
However, the use of the vaccines at present have some potential problems. The use of the live, virulent vaccines such as COCCIVAC and IMMUCOX, if not properly administered could result in some infection of the flock with coccidiosis. Alternatively, if not enough of any of the presently available vaccine is administered then the flock will not attain the necessary immunity to become resistant to coccidia infection. Additionally to promote complete protection the vaccines require the combination of numerous species and strains of Eimeria which may present problems in the proper formulation of the vaccine.
~~~~r,~e~
Such protection has only been accomplished through the use of live vaccines which contain oocysts from all relevant species of coccidia. Examples of vaccines presently commercially available include: COCCIVAC and IMMUCOX, both live, virulent vaccines containing oocysts from the seven species of Eimeria that parasitize domestic fowl, and PARACOX, a live, attenuated vaccine.
The vaccines are generally administered either in one large dose within the first few days of life or through the use of smaller doses given singularly or at separate times over the first few weeks of life.
However, the use of the vaccines at present have some potential problems. The use of the live, virulent vaccines such as COCCIVAC and IMMUCOX, if not properly administered could result in some infection of the flock with coccidiosis. Alternatively, if not enough of any of the presently available vaccine is administered then the flock will not attain the necessary immunity to become resistant to coccidia infection. Additionally to promote complete protection the vaccines require the combination of numerous species and strains of Eimeria which may present problems in the proper formulation of the vaccine.
~~~~r,~e~
The present invention provides for a recombinant coccidia comprising a relatively non-pathogenic strain of coccidia to which has been introduced DNA from one or more other strains or species of coccidia.
In an aspect of the invention, there is provided a recombinant coccidiosis vaccine comprising a relatively non-pathogenic strain of coccidia to which has been introduced sufficient DNA of one or more other strains or species of coccidia t o produce immunity to the multiple species in a host through inoculation of the host by the recombinant species.
A preferred embodiment of the present invention is illustrated in the attached drawings in which:
Figure lA is a photograph of ethidium bromide stained electrophoretically separated DNA from the parent strains and the recombinant strain in agarose gel before transfer of the DNA to nylon membrane, and Figure 1B is a photograph of X-ray film of the distribution of radioactive Yeast Artificial Chromosome (YAC) probe sequence bound to the DNA of Figure 1A after transfer to a nylon filter.
The present invention is based upon the principle that genomic DNA of related species of coccidia is similar enough in genomic organization and gene expression to permit productive recombination to take place if DNA from one species were to be introduced into cells of another species at the right time.
A method for isolating genomic DNA from coccidia was worked out based on isolation methods for filamentous fungal DNA. The method basically involves the extraction of the DNA by use of a French press followed by phenol and ethanol extractions. The isolated DNA is then transferred to an recipient host coccidium by suitable means to permit the expression of the donor DNA in the recipieint host coccidium. As coccidia DNA is present in the nucleus in discrete chromosomes, the suitable means for transfer will allow the donor DNA to either integrate into the host chromosomes or will allow the donor DNA to replicate as discrete additional chromosomal material. To permit the replication of the donor DNA as discrete chromosomes, chromosome functional sequences such as suitable telomeric sequences may have to be added. Such suitable telomeric sequences may be provided by packaging the DNA in a suitable vector acting as an artificial chromosome which contains such sequences for transfer of the DNA. Several such vectors have been developed for yeast which fortuitously have telomeric sequences derived from protozoan sources such as Tetrahymena. The use of such vectors has the added benefit that, not only do they permit the transfer of the DNA between species of coccidia, but also enable the cloning of individual genes of the coccidia in both prokaryotes and yeast as the vector acts as a plasmid in eukaryotes such as E. coli and as an artificial chromosome in yeast, in particular S, cerevisiae. Because the transferred DNA carries marker sequences from the vector, it is also possible to follow the transformation of the coccidia by detecting such sequences in genomic DNA of oocysts recovered after passage by use of conventional DNA-DNA hybridization methods or a sequence amplification method (DNA polymerase chain reaction, or PCR).
The packaged DNA is physically transferred into the recipient host organism by typical methods such as electroporation, microinjection or by in vitro incubation fi .. 8 of 'the DNA at high ionic concentration with the free living stages of the organism. Preferably, the transfer of the DNA is accomplished by elect roporation or microinjection, most preferably by electroporation.
Electroporation is a simple and rapid method of introducing foreign DNA into a cell line. Cells are subjected to a short electric discharge, apparently producing reversible pores in 'the cell membrane. DNA is then capable of passing into the cell where it may be incorporated into the genetic library.
In order to increase the selectivity of the recombinant coccidia, one or more selectable markers are preferably used. For example, the donor organism for the DNA preferrably encodes for a selectable marker, such as, for example, drug resistance while the recipient organism is devoid of the marker such as, for example, being sensitive to the drug. After production of the recombinant coccidium, the recombinant coccidium is passaged in a suitable host and the selectable marker is utilized to permit replication of only the recombinant organism. For example, if drug resistance i.s utilized as the selectable marker, the host animal is administered the drug to which the donor organism is resistant during passage of the recombinant organism. In this way only those recombinant organisms which carry the drug resistance marker from the donor DNA will replicate and reproduce.
The present invention is particularly suitable for use with coccidia of the genera Eimeria which infect poultry hosts. The DNA from donor organisms of one or more particularly pathogenic species is introduced into recipient host organisms of a less pathogenic species to produce a recombinant organism which will exhibit the less pathogenic infectivity of the host recipient organism while expressing the antigenic character of the more pathogenic donor. species. In this way, the recombinant organism will ~
w, g ~~~~~~r~c~3 enable the development of a safer vaccine to immunize the animal against the potentially lethal species of Eimeria.
For example, the DNA from E.tenella and/or E.necatrix which are the most pathogenic species of Eimeria to infect the chicken is incorporated into a less pathogenic species such as E.acervulina. Similarly, for the turkey the DNA from for example E. adenoides could be incorporated into a less pathogenic species of Eimeria which infects turkeys. For the purpose of the detailed examples following, the chicken model utilizing E. acervulina as the recipient host organism and E. tenella as the donor of the DNA was utilized. It will be appreciated by those of skill in the art that the methodology utilized in the examples is applicable to other systems, namely other species of ' Eimeria which infect chicken, other species of Eimeria which infect other hosts, and other species of coccidia in other hosts.
E. acervulina, the most prolific species of chicken coccidia, is only mildly pathogenic, causes maladsorption in the duodenum and is rarely, if ever, fatal. It evokes protective immunity with greater ease than E. tenella and has a shorter prepatent period of 5 days versus 7 days fox E, tenella. This gives an apparent advantage in that, with respect to the incorporated genes of E. tenella while being able to express antigenic determinants, the genes would not have sufficient time to encode for a complete E. tenella life cycle.
In terms of molecular biology, haploid E.
acervulina has a DNA content comparable to that of E.
tenella (7 .25 X 10-15 g/nucleus or about 69, 000 kb) (Cornelissen et a1 1984). This amount of DNA is about 17 times that of E. coli (4,000 kb), an organism used by Clarke et al (1987), Danforth and Augustine (1986) and Murray and Galuska (1987) to produce antigens.
Incorporating the E. tenella genes into E. acervulina not only results in a biological producer of. the desired to antigens, but also results in a .natural vector for use in a suitable vaccine. This approach circumvents the problems inherent in methods used by others where monoclonal antibodies and complementary DNAs have to be synthesized, purified and then used to produce antigens in unrelated organisms, before assembly into a subunit vaccine. This vaccine, if and when available, would still need to be injected or introduced into individual chickens.
By suitable techniques, the whole or part of the DNA from the nucleus of unsporulated E. tenella is isolated and inserted into unsporulated oocysts or sporozoites of E.
acervulina. Recombinant E. acervulina oocysts are then sporulated and the sporulated oocysts and/or sporozoites enriched by feeding them to coccidia-free days old chicks and the feces collected after a suitable patency period.
The presence of E. tenella DNA in the collected oocysts is confirmed and the progeny utilized to immunize birds which are then challenged with E. tenella as well as E.
acervulina.
A method for isolating genomic DNA from oocysts of Eimeria species was developed utilizing a French press and phenol and ethanol extractions. Such DNA appears to be very "crude"; it is sheared (<100 kbp in size), and it has variable amounts of contaminants (nuclease activity, polysaccharides and membraneous material) associated with it. This crude DNA responds to exogenously added, purified restriction endonucleases but does not yield very many discrete fragments like yeast DNA which is similar in genomic complexity. Not much evidence for repeat DNA
sequence was seen using usual methods. This suggests that the DNA is of low quality but that it was still useable in testing DNA transfer methods.
An existing vector containing protozoan teleomeric sequences and which functions as an artificial chromosome in yeast (YAC) was selected for packaging the donor DNA for transfer of the donor DNA into the recipient organism. A recent vector pYAC-RC (provided by Douglas Marchuk and Francis Collins, used in Cystic Fibrosis gene mapping), was utilized.
Since YAC vectors use telomeric sequences from a protozoan, such sequences are likely to also work in Emeria. Upon removal of a segment of the p-YAC-RC vector DNA by cutting with BamH1 nuclease (p-YAC-RC is a circular DNA plasmid), DNA sequences that function as telomeres (ends of chromosomes) are exposed. The remaining large DNA
fragment is further cut with SmaI nuclease to generate two "arms". E. tenella DNA cut with SmaI nuclease is combined with the vector fragments and ligated to create "chromosomal-like°' fragments with one or more of the "arms". On introducing these hybrid DNAs into E. acervulina oocysts, such sequences replicate alone or with host chromosomal DNA via integration during subsequent stages of chicken infection. Because the transferred DNA
carries YAC sequence it is possible to detect/identify such sequences in genomic DNA of oocysts recovered after passage through a chicken by use of conventional DNA-DNA
hybridization methods or a sequence amplification method (DNA polymerise chain reaction or PCR).
Construction of vectors containing the donor DNA
employs standard ligation techniques. Isolated DNA
fragments are cleaved, tailored and religated in the form desired to form the vectors required.
Cleavage or digestion'is performed by treating with restriction enzyme (or enzymes) in suitable buffer.
In general, about lE~g of DNA is used with about 1 unit of enzymes and about 20~.L of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are generally specified by the manufacturer of the enzyme. Owing to the size of the DNA from the coccidia incubation times of about 4 hours to 24 hours at 37°C are 12 ~~~V~~~
preferable. After incubation protein is removed by extraction with phenol and chloroform and nucleic acids recovered from the aqueous fraction by precipitation with ethanol.
Ligation refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments. For ligation, approximately equal molar amounts of the desired components suitably end tailored to provide correct matching are treated with about 10 units T4 DNA ligese per 0.5~,g of DNA. When cleaved vectors are used, it may by useful to prevent religation of the cleaved vector by pre-treatment o.f vector DNA with alkaline phosphatase.
Southern analysis is a method by which the presence of DNA sequences in a digest of DNA containing compositions is confirmed by hybridization to a known labelled oligonucleotide or DNA fragment. For the purposes herein unless otherwise provided, southern analysis shall mean separation of digest on a 0.8o agarose gel and transfer to nitrocellulose by the method of E. Southern, (1975) J. Mol Biol x$:503-517 and hybridization as described by T. Maniacus et al (1978) Cell ~ 687-701 Transformation means introducing DNA into an organism so that the DNA is replicable either as an extra chromosomal elemental or a chromosomal integrant.
The following example is given to illustrate the invention, but the invention is not to be limited thereto.
TSOT_,ATTOj~ OF FTAj RTA 00 YSTS AND SPC~RIyOTTF~
Unsporulated E. tenella and E. acervulina oocysts were isolated from fecal droppings of infected chickens by flotation in saturated NaCl. Tf desired, the ~..~
oocysts are allowed to sporulate by incubation in t he salt solution for 18 t o 20 hours at 30°C. The oocysts were surface-sterilized and decocted by washing in distilled water followed by treatment with 6a sodium hypochlorite far 10 min at 4°C. The decocted oocysts were washed thoroughly by centrifugation at 125 g for 1 min periods followed by resuspension. The washings were repeated at least 5 times in 0.9o NaCl and twice in homogenizing buffer containing 0.25 M sucrose and 0.1 M EDTA in 0.01 M Tris-HC1 buffer pH
In an aspect of the invention, there is provided a recombinant coccidiosis vaccine comprising a relatively non-pathogenic strain of coccidia to which has been introduced sufficient DNA of one or more other strains or species of coccidia t o produce immunity to the multiple species in a host through inoculation of the host by the recombinant species.
A preferred embodiment of the present invention is illustrated in the attached drawings in which:
Figure lA is a photograph of ethidium bromide stained electrophoretically separated DNA from the parent strains and the recombinant strain in agarose gel before transfer of the DNA to nylon membrane, and Figure 1B is a photograph of X-ray film of the distribution of radioactive Yeast Artificial Chromosome (YAC) probe sequence bound to the DNA of Figure 1A after transfer to a nylon filter.
The present invention is based upon the principle that genomic DNA of related species of coccidia is similar enough in genomic organization and gene expression to permit productive recombination to take place if DNA from one species were to be introduced into cells of another species at the right time.
A method for isolating genomic DNA from coccidia was worked out based on isolation methods for filamentous fungal DNA. The method basically involves the extraction of the DNA by use of a French press followed by phenol and ethanol extractions. The isolated DNA is then transferred to an recipient host coccidium by suitable means to permit the expression of the donor DNA in the recipieint host coccidium. As coccidia DNA is present in the nucleus in discrete chromosomes, the suitable means for transfer will allow the donor DNA to either integrate into the host chromosomes or will allow the donor DNA to replicate as discrete additional chromosomal material. To permit the replication of the donor DNA as discrete chromosomes, chromosome functional sequences such as suitable telomeric sequences may have to be added. Such suitable telomeric sequences may be provided by packaging the DNA in a suitable vector acting as an artificial chromosome which contains such sequences for transfer of the DNA. Several such vectors have been developed for yeast which fortuitously have telomeric sequences derived from protozoan sources such as Tetrahymena. The use of such vectors has the added benefit that, not only do they permit the transfer of the DNA between species of coccidia, but also enable the cloning of individual genes of the coccidia in both prokaryotes and yeast as the vector acts as a plasmid in eukaryotes such as E. coli and as an artificial chromosome in yeast, in particular S, cerevisiae. Because the transferred DNA carries marker sequences from the vector, it is also possible to follow the transformation of the coccidia by detecting such sequences in genomic DNA of oocysts recovered after passage by use of conventional DNA-DNA hybridization methods or a sequence amplification method (DNA polymerase chain reaction, or PCR).
The packaged DNA is physically transferred into the recipient host organism by typical methods such as electroporation, microinjection or by in vitro incubation fi .. 8 of 'the DNA at high ionic concentration with the free living stages of the organism. Preferably, the transfer of the DNA is accomplished by elect roporation or microinjection, most preferably by electroporation.
Electroporation is a simple and rapid method of introducing foreign DNA into a cell line. Cells are subjected to a short electric discharge, apparently producing reversible pores in 'the cell membrane. DNA is then capable of passing into the cell where it may be incorporated into the genetic library.
In order to increase the selectivity of the recombinant coccidia, one or more selectable markers are preferably used. For example, the donor organism for the DNA preferrably encodes for a selectable marker, such as, for example, drug resistance while the recipient organism is devoid of the marker such as, for example, being sensitive to the drug. After production of the recombinant coccidium, the recombinant coccidium is passaged in a suitable host and the selectable marker is utilized to permit replication of only the recombinant organism. For example, if drug resistance i.s utilized as the selectable marker, the host animal is administered the drug to which the donor organism is resistant during passage of the recombinant organism. In this way only those recombinant organisms which carry the drug resistance marker from the donor DNA will replicate and reproduce.
The present invention is particularly suitable for use with coccidia of the genera Eimeria which infect poultry hosts. The DNA from donor organisms of one or more particularly pathogenic species is introduced into recipient host organisms of a less pathogenic species to produce a recombinant organism which will exhibit the less pathogenic infectivity of the host recipient organism while expressing the antigenic character of the more pathogenic donor. species. In this way, the recombinant organism will ~
w, g ~~~~~~r~c~3 enable the development of a safer vaccine to immunize the animal against the potentially lethal species of Eimeria.
For example, the DNA from E.tenella and/or E.necatrix which are the most pathogenic species of Eimeria to infect the chicken is incorporated into a less pathogenic species such as E.acervulina. Similarly, for the turkey the DNA from for example E. adenoides could be incorporated into a less pathogenic species of Eimeria which infects turkeys. For the purpose of the detailed examples following, the chicken model utilizing E. acervulina as the recipient host organism and E. tenella as the donor of the DNA was utilized. It will be appreciated by those of skill in the art that the methodology utilized in the examples is applicable to other systems, namely other species of ' Eimeria which infect chicken, other species of Eimeria which infect other hosts, and other species of coccidia in other hosts.
E. acervulina, the most prolific species of chicken coccidia, is only mildly pathogenic, causes maladsorption in the duodenum and is rarely, if ever, fatal. It evokes protective immunity with greater ease than E. tenella and has a shorter prepatent period of 5 days versus 7 days fox E, tenella. This gives an apparent advantage in that, with respect to the incorporated genes of E. tenella while being able to express antigenic determinants, the genes would not have sufficient time to encode for a complete E. tenella life cycle.
In terms of molecular biology, haploid E.
acervulina has a DNA content comparable to that of E.
tenella (7 .25 X 10-15 g/nucleus or about 69, 000 kb) (Cornelissen et a1 1984). This amount of DNA is about 17 times that of E. coli (4,000 kb), an organism used by Clarke et al (1987), Danforth and Augustine (1986) and Murray and Galuska (1987) to produce antigens.
Incorporating the E. tenella genes into E. acervulina not only results in a biological producer of. the desired to antigens, but also results in a .natural vector for use in a suitable vaccine. This approach circumvents the problems inherent in methods used by others where monoclonal antibodies and complementary DNAs have to be synthesized, purified and then used to produce antigens in unrelated organisms, before assembly into a subunit vaccine. This vaccine, if and when available, would still need to be injected or introduced into individual chickens.
By suitable techniques, the whole or part of the DNA from the nucleus of unsporulated E. tenella is isolated and inserted into unsporulated oocysts or sporozoites of E.
acervulina. Recombinant E. acervulina oocysts are then sporulated and the sporulated oocysts and/or sporozoites enriched by feeding them to coccidia-free days old chicks and the feces collected after a suitable patency period.
The presence of E. tenella DNA in the collected oocysts is confirmed and the progeny utilized to immunize birds which are then challenged with E. tenella as well as E.
acervulina.
A method for isolating genomic DNA from oocysts of Eimeria species was developed utilizing a French press and phenol and ethanol extractions. Such DNA appears to be very "crude"; it is sheared (<100 kbp in size), and it has variable amounts of contaminants (nuclease activity, polysaccharides and membraneous material) associated with it. This crude DNA responds to exogenously added, purified restriction endonucleases but does not yield very many discrete fragments like yeast DNA which is similar in genomic complexity. Not much evidence for repeat DNA
sequence was seen using usual methods. This suggests that the DNA is of low quality but that it was still useable in testing DNA transfer methods.
An existing vector containing protozoan teleomeric sequences and which functions as an artificial chromosome in yeast (YAC) was selected for packaging the donor DNA for transfer of the donor DNA into the recipient organism. A recent vector pYAC-RC (provided by Douglas Marchuk and Francis Collins, used in Cystic Fibrosis gene mapping), was utilized.
Since YAC vectors use telomeric sequences from a protozoan, such sequences are likely to also work in Emeria. Upon removal of a segment of the p-YAC-RC vector DNA by cutting with BamH1 nuclease (p-YAC-RC is a circular DNA plasmid), DNA sequences that function as telomeres (ends of chromosomes) are exposed. The remaining large DNA
fragment is further cut with SmaI nuclease to generate two "arms". E. tenella DNA cut with SmaI nuclease is combined with the vector fragments and ligated to create "chromosomal-like°' fragments with one or more of the "arms". On introducing these hybrid DNAs into E. acervulina oocysts, such sequences replicate alone or with host chromosomal DNA via integration during subsequent stages of chicken infection. Because the transferred DNA
carries YAC sequence it is possible to detect/identify such sequences in genomic DNA of oocysts recovered after passage through a chicken by use of conventional DNA-DNA
hybridization methods or a sequence amplification method (DNA polymerise chain reaction or PCR).
Construction of vectors containing the donor DNA
employs standard ligation techniques. Isolated DNA
fragments are cleaved, tailored and religated in the form desired to form the vectors required.
Cleavage or digestion'is performed by treating with restriction enzyme (or enzymes) in suitable buffer.
In general, about lE~g of DNA is used with about 1 unit of enzymes and about 20~.L of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are generally specified by the manufacturer of the enzyme. Owing to the size of the DNA from the coccidia incubation times of about 4 hours to 24 hours at 37°C are 12 ~~~V~~~
preferable. After incubation protein is removed by extraction with phenol and chloroform and nucleic acids recovered from the aqueous fraction by precipitation with ethanol.
Ligation refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments. For ligation, approximately equal molar amounts of the desired components suitably end tailored to provide correct matching are treated with about 10 units T4 DNA ligese per 0.5~,g of DNA. When cleaved vectors are used, it may by useful to prevent religation of the cleaved vector by pre-treatment o.f vector DNA with alkaline phosphatase.
Southern analysis is a method by which the presence of DNA sequences in a digest of DNA containing compositions is confirmed by hybridization to a known labelled oligonucleotide or DNA fragment. For the purposes herein unless otherwise provided, southern analysis shall mean separation of digest on a 0.8o agarose gel and transfer to nitrocellulose by the method of E. Southern, (1975) J. Mol Biol x$:503-517 and hybridization as described by T. Maniacus et al (1978) Cell ~ 687-701 Transformation means introducing DNA into an organism so that the DNA is replicable either as an extra chromosomal elemental or a chromosomal integrant.
The following example is given to illustrate the invention, but the invention is not to be limited thereto.
TSOT_,ATTOj~ OF FTAj RTA 00 YSTS AND SPC~RIyOTTF~
Unsporulated E. tenella and E. acervulina oocysts were isolated from fecal droppings of infected chickens by flotation in saturated NaCl. Tf desired, the ~..~
oocysts are allowed to sporulate by incubation in t he salt solution for 18 t o 20 hours at 30°C. The oocysts were surface-sterilized and decocted by washing in distilled water followed by treatment with 6a sodium hypochlorite far 10 min at 4°C. The decocted oocysts were washed thoroughly by centrifugation at 125 g for 1 min periods followed by resuspension. The washings were repeated at least 5 times in 0.9o NaCl and twice in homogenizing buffer containing 0.25 M sucrose and 0.1 M EDTA in 0.01 M Tris-HC1 buffer pH
7.0 with added penicillin (100 units/ml) and streptomycin (50 ~.g/ml). The washed oocysts were centrifuged at 1,500 g for 10 min and the pellets resuspended and counted.
Sporocysts were released by fracturing the oocyst walls using unsiliconized glass beads. Oocysts were concentrated to approximately 8x106 oocysts/ml. 10.58 of 450-500 glass beads per 2.5m1 of oocyst suspension is placed in a one-ounce universal bottle and vortexed on high for 15 seconds. The beads were rinsed in sterile water and gravity filtered through a glass bead funnel in order to remove most of the wall debris and unbroken oocysts.
Glass bead funnels were prepared by filling 150m1 sintered glass Buchner funnels with 200~L unsiliconized glass beads up to a height of 5cm and rinsing once with filtered water before loading with the smashed oocyst solution.
Sporocysts were rinsed through the glass beads until oocysts are visible in the filtrate.
After filtering the sporocysts, they were centrifuged and resuspended at 10x106 oocyst/10m1 of medium-199. (Gibco Instant Tissue Culture Medium pH
adjusted to 7:5) Sporocysts were then incubated at 41°C
for 1/2 hour in Difco Bacto Bile Salts at a concentration of 50mg/l0ml of solution followed by Trypsin at lOmg/ml or solution and incubated at 41C for the additional one hour to release sporozoites. E. acervulina sporozoites are fragile relative to other stages in the Eimerian life cycle and should be kept on ice immediately after excystration and should be subjected to minimal centrifugation to retain viability.
Glass beads were rinsed once with Ringer's solution before sporozoite/bile/trypsin suspension were loaded onto the glass bead funnels and sporozoites passed through without the aid of suction. If significant residue blocks the filter, the surface beads were stirred using a wooden stirring rod. Sporozoites were then rinsed through until the effluent contained increased percentages (greater than lo) of sporulated oocysts. The sporozoites were purified by passing them through a second, clean glass bead filter using the same method described above. Sporozoites were then collected by centrifugation at medium speed for 3 minutes and resuspended in Ringer's solution. Recovery of sporzoites was usually 70% or better with purities greater than 98.50.
Glass beads were cleaned by soaking them in nitric acid followed by extensive rinsing in tap water.
Nitric acid is removed from the beads by stirring them in distilled water until the pH of the distilled water added remained constant.
E. tenella oocysts were collected and washed in JavexTM as set out above. They were then washed 3 times in 20mM Tris buffer (pH adjusted to 7.5) and lOmM EDTA
solution before smashing in the French press. Cells were concentrated and resuspended in approximately lOml of Tris/EDTA solution and passed once through the French press at 10-12 tonnes. Sodium dodecal sulfate (SDS) was added to a final concentration of to in order to denature protein.
Caution must be taken not to exceed to SDS since the DNA
may precipitate and centrifugation should be done at room temperature.
r'~. 15 ~~(.~~~~~~~
Proteinase K was added to a concentration of 100~.g/ml and the pH was adjusted to 8 using a concentrated Tris base. Digestion of protein was allowed to proceed overnight at 37°C. DNA was extracted with an equivolume of phenol and inverted gently (taking care not to shear DNA) for 5 minutes doing all extraction in the fumehood and the centrifuged at room temperature 10-15 minutes at 5000rpm.
If the top layer was not clear, the top layer was removed, reextracted with, phenol and centrifuged.
The top layer was pipetted off and extracted with equivolume of 50:50 phenol: half chloroform, inverted gently for 5 minutes and centrifuged for 10-15 minutes at 5000 rpm. The top layer was removed, extracted with equivolume of chloroform, inverted gently for 3-5 minutes and centrifuged for 10-15 minutes at 5000 rpm. The supernatant was removed and the molarity increased to 0.3M
by addition of 1/10 volume of 3NI sodium acetate. (pH of 5.2) Two volumes of absolute ethanol or 1 volume isopropanol was added quickly in order to precipitate DNA.
The precipitated DNA was centrifuge at 3000 rpm to form a pellet. The ethanol was carefully poured off so as not to drain off the soft pellet. DNA was solubilized in a minimum TE solution ensuring that all DNA has solubilized as some may remain as a clear gel. ire-boiled RNase was added up to 50~.g/ml and before incubation at 37C
for 1 hour a small aliquot was measured and its absorption level at 260nm recorded.
In order to remove RNase proteinase K was added up to 200~.1.g/ml and incubated at 37C for 1 hour. To purify DNA phenol, phenol/chloroform(1:1), and chloroform were added respectively at an equivolume. After each successive addition the extracts were inverted gently for 5 minutes, centrifuge 10-1.5 minutes at 5000 rpm and the bottom layer discarded.
16 ~~~U~~~~:3 After the last centrifugation was complete, the top layer was removed and the solution was placed into a dialysis bag and dialyzed in a sterile 1L beaker of TE
solution overnight in order to reduce nucleotides in the solution. The TE solution was replaced and allowed to sit for an additional 1 to 2 hours. A spectometer reading at 260nm of the TE solution should approach 0 as fewer nucleotides are being removed from the dialysed DNA
solution.
After dialysis spectrometer readings were taken at wavelengths of 260nm and 280nm. One OD unit at 260nm is equivalue to 50~g/ml of DNA. A ratio of OD units from readings at wavelengths 260nm and 280nm indicate the purity of the sample. Ratios between 1.6 and 1.8 indicate pure DNA whereas ratios of 2 and upwards indicate significant residue present.
Three samples of E.tenella DNA (150 ~1g in 250 ~Ll final volume of digestion buffer) were digested for 0.5, 2, and 4 hr respectively at 37°C with 10 units of Smal endonuclease (cuts at sequence: 5'-NNCCC< > GGGNN-3'). 15 ~.g of YAC vector (plasmid pYAC-RC) was digested under the same conditions with 1 unit each of BamH1 and SmaI. After stopping the respective reactions with 0.1o SDS and 25mM
EDTA at 70°C for 5 min, all of the samples were pooled and extracted twice with 1 volume of, phenol-chloroform. DNA
was precipitated with 2.5 volumes of 95o ethanol (v/v) and centrifugation (Beckman 12 microfuge). DNA was semi-dried with N2 gas and dissolved in 250.1 of 1mM Dithothreitol in H20 at 36°C for 24 h before addition of 5X ligation buffer (66mM Tris-HC1 pH 7.8, 6mM MgCl2 final cone.), freshly made ATP (0.5mM final) and 30 ~1 (60 units) of T4 ligase (Pharmacia). Ligation of E.tenella DNA to plasmid vector ~~~(~~~~~
DNA was carried out for 30 hr at 5°C, before further dilution with 1X ligation buffer without ligase to approx.
500,1 final volume. Ligated DNA was subsequently stored at 4°C until used.
Sporozoites were prepared as described earlier.
The cell-porator unit supplied by Bethesda Research Laboratories Life Technologies, Inc, in conjunction with a cell-porator voltage were used containing two electrodes 4cm apart, 1 ml of sporozoite suspension at concentrations greater than 1x106/ml was loaded into the chamber using a micro pipette. Although cell fusions may occur at such high concentrations, a greater percent of transformation is thought to occur when cell concentrations exceed 1x106/ml.
DNA was added to each cell suspension at a concentration not less than 20~,g/ml. Chambers were kept an ice while cells were subjected to the electrical pulses at 400V, 330~1F capacitance, 100kV booster and high resistance. The sporozoite suspensions were thereafter allowed to remain on the lab bench for at least 10 minutes in order to enhance DNA uptake.
Several trials were carried out using different stages of the Eimerian life cycle, sporocysts and oocysts.
As well some sporozoite and oocyst suspensions containing acridine orange in addition to the DNA were studied as acridine orange may increase DNA uptake.
Groups of days old chicks were inoculated per os with about 500,000 sporozoites each of untreated E.acervulina, E.acervulina into which had been tranferred Clostridium sp. DNA, E.acervulina into which had been transferred E. tenella DNA and E.acervulina into which had been transferred acridine orange labelled E. tenella DNA.
Thirteen days after inoculation each group was challenged blind with 50,000 E. tenella oocysts per bird. Six days after challenge, each bird was scored blind for lesion size and the results tabulated.
i) Cenomic DNA- Approx. 50 ug of DNA from E_tenella, E.acerv~lina and the two putative E.acervulina x E. tenella recombinants isolated as desribed above were each incubated with SO units of BamHl enzyme (cuts at sequence: 5'NNG< >GATCCNN-3') at 37°C for 4 hr and 24 hr in buffer containing lOmM Tris.HCl pH 7.8, 50mM KCl, O.lmM
EDTA, 1mM Dithiothreitol. Reactions were stopped by addition of sodium dodecylsulphate (0.2o final) and EDTA
(25mM) .
ii) Marker DNA: plasmid pYAC-RC (5 ~.lg) and lambda bacteriophage, Charon 4A (5~.g) were digested as described fur genomic DNA (see above) with 1 unit each of BamHl, HindIII and Eco Rl.
b) F~ectrophores~s, DNA Transfer to Membranes and DNA samples were loaded into slots (lanes in a l5cm x 20cm, 0.80 (w/v) agarose slab containing Tris-Acetate, EDTA, ethidium bromide (5ug/ml) buffer and electrophoresed (submerged in same buffer without ethidium bromide) for 6hrs at 40mA, 18°C. DNA in gel was photographed (Polaroid type 52 film using UV light.and filter). Gel was further treated with 100mM HC1 at 20°C for 10 min. and 400mM NaOH
for 30 min to break and denature the DNA strands. After three brief washes in gel running buffer, DNA in the gel was electrophoretically transferred to Hybond-NTM (Amersham) 19 ~~~Jr~~~
0.45 ~m nylon membrane (same size as gel). The membrane was rinsed in a solution containing 1M NaCl and 1mM EDTA
and dried by air (30min) and heat (30°C, 1 hr in vaccuo).
The membrane was incubated for 1 hr at 68°C in 200 ml of hybridization buffer (1M NaCl, 1mM EDTA, 0.1o SDS, 10~.g/ml sheared and dematured calf thymus DNA (Sigma Chem).
Hybridization was carried out in a plastic bag containing ml of same buffer stock with 10~ cpm of random primed pYAC-RC (0.5 ug) template. Membrane was washed four times 10 with 100m1 of hybridization buffer at 1X and four times with 100m1 of hybridization buffer at 0.5X at 68°C. Filter was air dried and exposed to Kodak XR X-ray film with single screen for three days and 5 days.
Differences in samples of DNA were noted during processing of E. acervulina and E. tenella DNA. After French pressing, the E. acervulina solution seemed very gel-like, whereas the viscosity of the E. tenella did not visibly change. Upon phenol addition, E. acervulina DNA
formed a very tight white precipitate at the interface whereas E. tenella precipitate breaks up at the interface.
After addition of ethanol, E. tenella turns the DNA
suspension cloudy whereas the E. acervulina suspension remains clear and DNA is visible as a fluffy cotton ball type precipitate. E. tenella DNA precipitate after freezing is a fine powder. In general the DNA samples prepared from the first generation electroporated oocysts appeared as the unaltered E. acervulina DNA however, after precipitation with ethanol some of the precipitate floated and some separated and sank to the bottom of the tube.
This may be an indication of an alteration in the E.
acervul.ina DNA.
a Fig. 1A shows a photograph of ethidium bromide stained, electrophoretically separated DNA in agarose gel before 5 transfer of DNA to nylon membrane. Fig 1B shows a photograph of X-ray film indicating distribution of radioactive YAC probe sequence bound to DNA on the .nylon filter.
10 Lanes a and m, negative control (does not hybridize to YAC
probe as expected) and DNA size markers: lambda bacteriophage Charon 4A DNA digested with BamHl, HindIII
and EcoRl. Charon 4A digest should yield 11 fragments but only six large fragments 4.9-11.5 kbp in size (see six bars 15 right side of photo) were observed.
Lane h, BamH1+ HindIII + SmaI digested PYAC-RC (positive control) should yield at least eight ethidium bromide staining bands (more with partial digestion as appears to 20 be the case as SmaI does nat cut well). Probe made from this DNA hybridizes to all fragments (Fig. 1B).
Lanes b-f and lanes i-1 correspond to Emeria sp. DNA
digested with BamH1 (see Experimental for details). Lane ~ DNA from a Clostridium sp. also isolated from chicken faeces (serves as another negative hybridization control).
E.tenella DNA (lanes b and c), E. acervulina (lanes d, e) and putative E. acervulina x E.tenella recombinants fixst trial (lanes i, j) and ~on~, rial (k and 1). Lanes b, d, g, j and k are DNA samples digested for 4 hrs at 37°C.
Lanes c, e, f, i, and 1 are samples of DNA digested with same amount of BamHl enzyme at 37°C but for 24hrs.
b) Tn-.rpretations:
Fig. 1A indicates that all DNA samples have endogenous nucleases (compare 4 hrs vs. 24 hr digests).
Other tests indicated that this nuclease activity is ~7~~i~~~~
inhibited mostly by EDTA, requiring MgCl2 which is present in the restriction enzyme buffer. There is also evidence that the "crude" DNA samples contain (see ethidium bromide staining material particularly at top of gel) cellular debris rich in polysaccharide and lipid. This material is entangled with high molecular DNA and is released from extensively degraded DNA (24hr samples); most of it floated out of the gel wells during electrophoresis, the rest escaped during handling of the gel. for photography. These observation are very typical of crude DNA preps of most lower organisms.
No YAC probe hybridization to lamda Charon 4A in spite of very high concentration of this DNA which is a very good control for probe specificity, suggesting that hybridization to extra bands in lane j may be real. No hybridization to Clostridium sp DNA observed also is another good sign of specificity.
No hybridization to low molecular weight DNA of Emeria parental DNAs (4hr digests); slightly more to E.tenella than E.acervulzna DNA. The ethidium bromide staining patterns (FiglA) of Eimeria parental DNA show traces of repeat sequences which do not hybridize to YAC
probe. However the E.acervulina recombinant # 1 DNA which gave the lowest lesion score (1.2) has a pattern of hybridization a bit like E.tenella DNA but it also has two positive hybridization bands, one being similar in size to YAC plasmid DNA used originally in the ligations. In late digestion (24hr) all of this hybridization material is likely lost as might be expected by extensive endogenous nuclease nicking of the DNA.
Recombinant # 2 DNA also has a small amount of hybridization in the same position but the concentration is much lower. Since these samples represents pools of oocysts this could mean that #1 has been amplified more than #2.
~:~~~~~~9 The positive bands in lane j tend to indicate the presence of true YAC sequence, but not all of the sequence. This would be the simplest and most consistent interpretation of the data and would not be surprising because the specific E.tenella DNA or E.acervulina DNA
associated with it would could have fused and discarded either all or part of the YAC arms through sequences related to the Trpl, Ura3, TEL or His3 gene sequences. The yeast genes are conserved in lower eukaryotes and so possibly is the TEL gene.
The observed bands may be related to Eimeria repeat sequences which would require highly intact DNA to confirm but the control data do not strongly support this possibility. The possibility of spurious hybridization is also unlikely due to predictability of results from the other controls. Also the same trend was continued when hybridizations were repeated on a more limited scale by dot method due to lack of sample.
Groups of days old chicks were inoculated with samples of each of untreated E. acervulina, E. acervulina in to which have been transferred Clostridium sp. DNA, E.
acervulina in which have been transferred E. tenella DNA, and E. acervulina in to which have been transferred acridine orange labelled E. tenella DNA. Thirteen days after inoculation the chicks were challenged with 50,000 E.
tenella oocysts and after suitable patency period, birds were explored for lesion size. Summary results of a number of tests are given in the following Tables 1 and 2.
Group Ave Lesion Score Redy~!esior~/Total Control 3.0 0/8 Clostridium DNA 2.7 2./14 E. tenella DNA 2.8 3/13 Labelled E. tenella DNA trial#1 1.5 6/7 trial#2 1.2 TABr.E 2 (~rnnn 2lzrcrarro T.oeinn Cnnro Not porated 3.0 Control Porated with 3.3 Clostridium DNA
Porated with 2.8 E. tenella DNA
Porated with labelled E. tenella DNA
trial #1 1.5 trial #2 1.2 Not porated 2.6 Sporozoites Not porated 3.3 Oocysts 2n Porated with 2.1 Clostridium DNA
Porated with 2.7 E. tenella DNA
The above results clearly demonstrate the effectiveness of the transfered DNA of the E, tenella donor to confer immunity to E. tenella .in birds immunized with the recombinant E. acervulina. This is evidenced by the reduced lesion scores in those animals inoculated with the recombinant organism. The reduct_Lon in lesion scores seen with the Clostridium sp. was postulated to arise as a result of possibility of cross contamination between the birds inoculated with the two recombinant organisms. It is also clear from the results that, at least under the conditions selected for the electroporation, the use of the acridine orange label increases significantly the efficiency of the transfer of the donor DNA to the recipient host. The average lesion scores of 1.5 and 1.2 and the degree of protection with 6 out of 7 birds having significantly reduced lesions are similar to results that are normally observed upon challenge of birds inoculated with native E. tenella in traditional immunization programs.
The above example clearly demonstrates the ability of the recombinant coccidia in the present invention to confer immunity in an animal host against infection by the coccidium which acts as a donor organism. ' While the example has only utilized whole DNA from one species it would be readily apparent to those of skill in the art that the invention could be practiced utilizing more than one species as a donor organism thereby conferring immunity to multiple specie of coccidia in an animal host. Also as the understanding of coccidial antigenic determinants and the immunity evoked in the host animal by immunization with a coccidia vaccine increases in W 25 ~~~~~?r~~~
the future the invention may be utilized to take advantage of this increased knowledge. For example, as significant antigens and the genes encoding them are identified, such genes may be isolated and packaged in accordance with the present invention to permit the expression of the gene and production of the antigenic determinant in the recombinant coccidium. Such genes could include genes from many species of coccidia thereby conferring immunity to a multitude of species through the use of the recombinant coccidium of the present invention.
The recombinant coccidia of the present invention permits the development of novel vaccines which induce immunity to more pathogenic species of coccidia by incorporating the DNA from such species into less pathogenic species. Such a vaccine has a major impact on the concept of coccidial vaccine manufacturing. The vaccine will be used with less impunity than present live vaccines and the industry now has a viable and longer-lasting alternative to medication. By utilizing a less pathogenic species of coccidia as the recipient, the potential for accidentally inducing disease in a flock through misadministration of the vaccine is greatly reduced.
Vaccine doses can be increased relative to traditional vaccines to ensure that even if individual chicks receive reduced doses, there will be sufficient antigen present to confer immunity. Unlike present live vaccines, the vaccine of the present invention does not require anticoccidials either in the feed or the water to assist in control of coccidiosis.
Although various preferred embodiments of the present invention have been described herein in detail, it will be appreciated by 'those skilled in the art, that variations may be made thereto without departing from the spirit of the invention or the scope of the appended claims.
t~B~~~'~~~~
BIBLIOGRAPHY
Bhogal, Balbir S.et al (1987), "Generation and Functional characterization of Eimeria Tenella immune chicken T-cell clones", Avian Imm, pages 127-144.
Bhogal, B.S.et al (1992), "Potential of a recombinant antigen as a prophylactic vaccine for day-old broiler chickens agains Eimeria acervuline and Eimeria tenella infections", Veterinary Immunology and immunopathology, ~.2,: 323, 335 .
Brothers, Virginia M. et al (1988), "Characterization of a surface antigen of Eimeria tenella sporozoites and synthesis from a cloned cDrIA in Escherichia coli", Mol Biochem Parasitology 2$: 235-248.
Castle, Marc D. et al (1991), "Characterization of a Recombinant Eimeria acervulina antigen expressed in sporozoite and merozoite developmental stages" J.
Parasitology 2Z: 384-390.
Clarke, Lorraine E.et al (1987), "Isolation of a _ amp3 genomic recombinants coding for antigens of Eimeria tenella", Mol. Biochem Parasitology ,2~: 79-87.
Danforth, H.D.(1986), "Use of Hybridoma Antibodies combined with genetic engineering in the study of protozoan parasites: A review", in McDougall et al (1986).
Hein, Helen E.(1976), "Eimeria ~cervulina, E. brunetti, E.
maxima, and E. necatrix: Low Doses of Oocysts to Immunize Young Chickens",Exp Parasitology 4Q: 250-260.
Jenkins, Mark C. (1988), "Eimeria acervulina: DNA Cloning and Characterization of Recombinant Sporozoite and Merozoite Antigens", Exp Parasiltology .~.~: 96-107) Lillehoj, Hyun S. et al (1988), "Eimeria acervulina:
Evaluation of the Cellular and Antibody Responses to the Recombinant Coccidial Antigens in B-Congenic Chickens", Exp Parasitologyu .~Z: 148-158.
Long, Peter L.(1990), "Coccidiosis of Man and Domestic Animal", CRC Pres Inc.
McDougall, Larry R.et al (1986), "Research in Avian Coccidia", University of Georgia.
Murray, Keith P. et al (1986), "Eimeria tenella - In vivo immunization studies with sporozoite antigen", in McDougall et al (1986).
Profous-Juchelka, Helen et al (1988), "Identification and characterization of cDNA clones encoding antigens of Eimeria tenella", Mol Biochem Parasitology ,~Q: 233-242.
Wisher, Martin H. (1986), "Identification of the sporozoite antigens of Eimeria tenella" Mol. Biocem Parasitology ~: 7-15.
Wong, R.B., and Thammana P. (1986), "Monoclonal Antibody Defined Stage Specific And Stage Independent Antigens of Eimeria tenella",
Sporocysts were released by fracturing the oocyst walls using unsiliconized glass beads. Oocysts were concentrated to approximately 8x106 oocysts/ml. 10.58 of 450-500 glass beads per 2.5m1 of oocyst suspension is placed in a one-ounce universal bottle and vortexed on high for 15 seconds. The beads were rinsed in sterile water and gravity filtered through a glass bead funnel in order to remove most of the wall debris and unbroken oocysts.
Glass bead funnels were prepared by filling 150m1 sintered glass Buchner funnels with 200~L unsiliconized glass beads up to a height of 5cm and rinsing once with filtered water before loading with the smashed oocyst solution.
Sporocysts were rinsed through the glass beads until oocysts are visible in the filtrate.
After filtering the sporocysts, they were centrifuged and resuspended at 10x106 oocyst/10m1 of medium-199. (Gibco Instant Tissue Culture Medium pH
adjusted to 7:5) Sporocysts were then incubated at 41°C
for 1/2 hour in Difco Bacto Bile Salts at a concentration of 50mg/l0ml of solution followed by Trypsin at lOmg/ml or solution and incubated at 41C for the additional one hour to release sporozoites. E. acervulina sporozoites are fragile relative to other stages in the Eimerian life cycle and should be kept on ice immediately after excystration and should be subjected to minimal centrifugation to retain viability.
Glass beads were rinsed once with Ringer's solution before sporozoite/bile/trypsin suspension were loaded onto the glass bead funnels and sporozoites passed through without the aid of suction. If significant residue blocks the filter, the surface beads were stirred using a wooden stirring rod. Sporozoites were then rinsed through until the effluent contained increased percentages (greater than lo) of sporulated oocysts. The sporozoites were purified by passing them through a second, clean glass bead filter using the same method described above. Sporozoites were then collected by centrifugation at medium speed for 3 minutes and resuspended in Ringer's solution. Recovery of sporzoites was usually 70% or better with purities greater than 98.50.
Glass beads were cleaned by soaking them in nitric acid followed by extensive rinsing in tap water.
Nitric acid is removed from the beads by stirring them in distilled water until the pH of the distilled water added remained constant.
E. tenella oocysts were collected and washed in JavexTM as set out above. They were then washed 3 times in 20mM Tris buffer (pH adjusted to 7.5) and lOmM EDTA
solution before smashing in the French press. Cells were concentrated and resuspended in approximately lOml of Tris/EDTA solution and passed once through the French press at 10-12 tonnes. Sodium dodecal sulfate (SDS) was added to a final concentration of to in order to denature protein.
Caution must be taken not to exceed to SDS since the DNA
may precipitate and centrifugation should be done at room temperature.
r'~. 15 ~~(.~~~~~~~
Proteinase K was added to a concentration of 100~.g/ml and the pH was adjusted to 8 using a concentrated Tris base. Digestion of protein was allowed to proceed overnight at 37°C. DNA was extracted with an equivolume of phenol and inverted gently (taking care not to shear DNA) for 5 minutes doing all extraction in the fumehood and the centrifuged at room temperature 10-15 minutes at 5000rpm.
If the top layer was not clear, the top layer was removed, reextracted with, phenol and centrifuged.
The top layer was pipetted off and extracted with equivolume of 50:50 phenol: half chloroform, inverted gently for 5 minutes and centrifuged for 10-15 minutes at 5000 rpm. The top layer was removed, extracted with equivolume of chloroform, inverted gently for 3-5 minutes and centrifuged for 10-15 minutes at 5000 rpm. The supernatant was removed and the molarity increased to 0.3M
by addition of 1/10 volume of 3NI sodium acetate. (pH of 5.2) Two volumes of absolute ethanol or 1 volume isopropanol was added quickly in order to precipitate DNA.
The precipitated DNA was centrifuge at 3000 rpm to form a pellet. The ethanol was carefully poured off so as not to drain off the soft pellet. DNA was solubilized in a minimum TE solution ensuring that all DNA has solubilized as some may remain as a clear gel. ire-boiled RNase was added up to 50~.g/ml and before incubation at 37C
for 1 hour a small aliquot was measured and its absorption level at 260nm recorded.
In order to remove RNase proteinase K was added up to 200~.1.g/ml and incubated at 37C for 1 hour. To purify DNA phenol, phenol/chloroform(1:1), and chloroform were added respectively at an equivolume. After each successive addition the extracts were inverted gently for 5 minutes, centrifuge 10-1.5 minutes at 5000 rpm and the bottom layer discarded.
16 ~~~U~~~~:3 After the last centrifugation was complete, the top layer was removed and the solution was placed into a dialysis bag and dialyzed in a sterile 1L beaker of TE
solution overnight in order to reduce nucleotides in the solution. The TE solution was replaced and allowed to sit for an additional 1 to 2 hours. A spectometer reading at 260nm of the TE solution should approach 0 as fewer nucleotides are being removed from the dialysed DNA
solution.
After dialysis spectrometer readings were taken at wavelengths of 260nm and 280nm. One OD unit at 260nm is equivalue to 50~g/ml of DNA. A ratio of OD units from readings at wavelengths 260nm and 280nm indicate the purity of the sample. Ratios between 1.6 and 1.8 indicate pure DNA whereas ratios of 2 and upwards indicate significant residue present.
Three samples of E.tenella DNA (150 ~1g in 250 ~Ll final volume of digestion buffer) were digested for 0.5, 2, and 4 hr respectively at 37°C with 10 units of Smal endonuclease (cuts at sequence: 5'-NNCCC< > GGGNN-3'). 15 ~.g of YAC vector (plasmid pYAC-RC) was digested under the same conditions with 1 unit each of BamH1 and SmaI. After stopping the respective reactions with 0.1o SDS and 25mM
EDTA at 70°C for 5 min, all of the samples were pooled and extracted twice with 1 volume of, phenol-chloroform. DNA
was precipitated with 2.5 volumes of 95o ethanol (v/v) and centrifugation (Beckman 12 microfuge). DNA was semi-dried with N2 gas and dissolved in 250.1 of 1mM Dithothreitol in H20 at 36°C for 24 h before addition of 5X ligation buffer (66mM Tris-HC1 pH 7.8, 6mM MgCl2 final cone.), freshly made ATP (0.5mM final) and 30 ~1 (60 units) of T4 ligase (Pharmacia). Ligation of E.tenella DNA to plasmid vector ~~~(~~~~~
DNA was carried out for 30 hr at 5°C, before further dilution with 1X ligation buffer without ligase to approx.
500,1 final volume. Ligated DNA was subsequently stored at 4°C until used.
Sporozoites were prepared as described earlier.
The cell-porator unit supplied by Bethesda Research Laboratories Life Technologies, Inc, in conjunction with a cell-porator voltage were used containing two electrodes 4cm apart, 1 ml of sporozoite suspension at concentrations greater than 1x106/ml was loaded into the chamber using a micro pipette. Although cell fusions may occur at such high concentrations, a greater percent of transformation is thought to occur when cell concentrations exceed 1x106/ml.
DNA was added to each cell suspension at a concentration not less than 20~,g/ml. Chambers were kept an ice while cells were subjected to the electrical pulses at 400V, 330~1F capacitance, 100kV booster and high resistance. The sporozoite suspensions were thereafter allowed to remain on the lab bench for at least 10 minutes in order to enhance DNA uptake.
Several trials were carried out using different stages of the Eimerian life cycle, sporocysts and oocysts.
As well some sporozoite and oocyst suspensions containing acridine orange in addition to the DNA were studied as acridine orange may increase DNA uptake.
Groups of days old chicks were inoculated per os with about 500,000 sporozoites each of untreated E.acervulina, E.acervulina into which had been tranferred Clostridium sp. DNA, E.acervulina into which had been transferred E. tenella DNA and E.acervulina into which had been transferred acridine orange labelled E. tenella DNA.
Thirteen days after inoculation each group was challenged blind with 50,000 E. tenella oocysts per bird. Six days after challenge, each bird was scored blind for lesion size and the results tabulated.
i) Cenomic DNA- Approx. 50 ug of DNA from E_tenella, E.acerv~lina and the two putative E.acervulina x E. tenella recombinants isolated as desribed above were each incubated with SO units of BamHl enzyme (cuts at sequence: 5'NNG< >GATCCNN-3') at 37°C for 4 hr and 24 hr in buffer containing lOmM Tris.HCl pH 7.8, 50mM KCl, O.lmM
EDTA, 1mM Dithiothreitol. Reactions were stopped by addition of sodium dodecylsulphate (0.2o final) and EDTA
(25mM) .
ii) Marker DNA: plasmid pYAC-RC (5 ~.lg) and lambda bacteriophage, Charon 4A (5~.g) were digested as described fur genomic DNA (see above) with 1 unit each of BamHl, HindIII and Eco Rl.
b) F~ectrophores~s, DNA Transfer to Membranes and DNA samples were loaded into slots (lanes in a l5cm x 20cm, 0.80 (w/v) agarose slab containing Tris-Acetate, EDTA, ethidium bromide (5ug/ml) buffer and electrophoresed (submerged in same buffer without ethidium bromide) for 6hrs at 40mA, 18°C. DNA in gel was photographed (Polaroid type 52 film using UV light.and filter). Gel was further treated with 100mM HC1 at 20°C for 10 min. and 400mM NaOH
for 30 min to break and denature the DNA strands. After three brief washes in gel running buffer, DNA in the gel was electrophoretically transferred to Hybond-NTM (Amersham) 19 ~~~Jr~~~
0.45 ~m nylon membrane (same size as gel). The membrane was rinsed in a solution containing 1M NaCl and 1mM EDTA
and dried by air (30min) and heat (30°C, 1 hr in vaccuo).
The membrane was incubated for 1 hr at 68°C in 200 ml of hybridization buffer (1M NaCl, 1mM EDTA, 0.1o SDS, 10~.g/ml sheared and dematured calf thymus DNA (Sigma Chem).
Hybridization was carried out in a plastic bag containing ml of same buffer stock with 10~ cpm of random primed pYAC-RC (0.5 ug) template. Membrane was washed four times 10 with 100m1 of hybridization buffer at 1X and four times with 100m1 of hybridization buffer at 0.5X at 68°C. Filter was air dried and exposed to Kodak XR X-ray film with single screen for three days and 5 days.
Differences in samples of DNA were noted during processing of E. acervulina and E. tenella DNA. After French pressing, the E. acervulina solution seemed very gel-like, whereas the viscosity of the E. tenella did not visibly change. Upon phenol addition, E. acervulina DNA
formed a very tight white precipitate at the interface whereas E. tenella precipitate breaks up at the interface.
After addition of ethanol, E. tenella turns the DNA
suspension cloudy whereas the E. acervulina suspension remains clear and DNA is visible as a fluffy cotton ball type precipitate. E. tenella DNA precipitate after freezing is a fine powder. In general the DNA samples prepared from the first generation electroporated oocysts appeared as the unaltered E. acervulina DNA however, after precipitation with ethanol some of the precipitate floated and some separated and sank to the bottom of the tube.
This may be an indication of an alteration in the E.
acervul.ina DNA.
a Fig. 1A shows a photograph of ethidium bromide stained, electrophoretically separated DNA in agarose gel before 5 transfer of DNA to nylon membrane. Fig 1B shows a photograph of X-ray film indicating distribution of radioactive YAC probe sequence bound to DNA on the .nylon filter.
10 Lanes a and m, negative control (does not hybridize to YAC
probe as expected) and DNA size markers: lambda bacteriophage Charon 4A DNA digested with BamHl, HindIII
and EcoRl. Charon 4A digest should yield 11 fragments but only six large fragments 4.9-11.5 kbp in size (see six bars 15 right side of photo) were observed.
Lane h, BamH1+ HindIII + SmaI digested PYAC-RC (positive control) should yield at least eight ethidium bromide staining bands (more with partial digestion as appears to 20 be the case as SmaI does nat cut well). Probe made from this DNA hybridizes to all fragments (Fig. 1B).
Lanes b-f and lanes i-1 correspond to Emeria sp. DNA
digested with BamH1 (see Experimental for details). Lane ~ DNA from a Clostridium sp. also isolated from chicken faeces (serves as another negative hybridization control).
E.tenella DNA (lanes b and c), E. acervulina (lanes d, e) and putative E. acervulina x E.tenella recombinants fixst trial (lanes i, j) and ~on~, rial (k and 1). Lanes b, d, g, j and k are DNA samples digested for 4 hrs at 37°C.
Lanes c, e, f, i, and 1 are samples of DNA digested with same amount of BamHl enzyme at 37°C but for 24hrs.
b) Tn-.rpretations:
Fig. 1A indicates that all DNA samples have endogenous nucleases (compare 4 hrs vs. 24 hr digests).
Other tests indicated that this nuclease activity is ~7~~i~~~~
inhibited mostly by EDTA, requiring MgCl2 which is present in the restriction enzyme buffer. There is also evidence that the "crude" DNA samples contain (see ethidium bromide staining material particularly at top of gel) cellular debris rich in polysaccharide and lipid. This material is entangled with high molecular DNA and is released from extensively degraded DNA (24hr samples); most of it floated out of the gel wells during electrophoresis, the rest escaped during handling of the gel. for photography. These observation are very typical of crude DNA preps of most lower organisms.
No YAC probe hybridization to lamda Charon 4A in spite of very high concentration of this DNA which is a very good control for probe specificity, suggesting that hybridization to extra bands in lane j may be real. No hybridization to Clostridium sp DNA observed also is another good sign of specificity.
No hybridization to low molecular weight DNA of Emeria parental DNAs (4hr digests); slightly more to E.tenella than E.acervulzna DNA. The ethidium bromide staining patterns (FiglA) of Eimeria parental DNA show traces of repeat sequences which do not hybridize to YAC
probe. However the E.acervulina recombinant # 1 DNA which gave the lowest lesion score (1.2) has a pattern of hybridization a bit like E.tenella DNA but it also has two positive hybridization bands, one being similar in size to YAC plasmid DNA used originally in the ligations. In late digestion (24hr) all of this hybridization material is likely lost as might be expected by extensive endogenous nuclease nicking of the DNA.
Recombinant # 2 DNA also has a small amount of hybridization in the same position but the concentration is much lower. Since these samples represents pools of oocysts this could mean that #1 has been amplified more than #2.
~:~~~~~~9 The positive bands in lane j tend to indicate the presence of true YAC sequence, but not all of the sequence. This would be the simplest and most consistent interpretation of the data and would not be surprising because the specific E.tenella DNA or E.acervulina DNA
associated with it would could have fused and discarded either all or part of the YAC arms through sequences related to the Trpl, Ura3, TEL or His3 gene sequences. The yeast genes are conserved in lower eukaryotes and so possibly is the TEL gene.
The observed bands may be related to Eimeria repeat sequences which would require highly intact DNA to confirm but the control data do not strongly support this possibility. The possibility of spurious hybridization is also unlikely due to predictability of results from the other controls. Also the same trend was continued when hybridizations were repeated on a more limited scale by dot method due to lack of sample.
Groups of days old chicks were inoculated with samples of each of untreated E. acervulina, E. acervulina in to which have been transferred Clostridium sp. DNA, E.
acervulina in which have been transferred E. tenella DNA, and E. acervulina in to which have been transferred acridine orange labelled E. tenella DNA. Thirteen days after inoculation the chicks were challenged with 50,000 E.
tenella oocysts and after suitable patency period, birds were explored for lesion size. Summary results of a number of tests are given in the following Tables 1 and 2.
Group Ave Lesion Score Redy~!esior~/Total Control 3.0 0/8 Clostridium DNA 2.7 2./14 E. tenella DNA 2.8 3/13 Labelled E. tenella DNA trial#1 1.5 6/7 trial#2 1.2 TABr.E 2 (~rnnn 2lzrcrarro T.oeinn Cnnro Not porated 3.0 Control Porated with 3.3 Clostridium DNA
Porated with 2.8 E. tenella DNA
Porated with labelled E. tenella DNA
trial #1 1.5 trial #2 1.2 Not porated 2.6 Sporozoites Not porated 3.3 Oocysts 2n Porated with 2.1 Clostridium DNA
Porated with 2.7 E. tenella DNA
The above results clearly demonstrate the effectiveness of the transfered DNA of the E, tenella donor to confer immunity to E. tenella .in birds immunized with the recombinant E. acervulina. This is evidenced by the reduced lesion scores in those animals inoculated with the recombinant organism. The reduct_Lon in lesion scores seen with the Clostridium sp. was postulated to arise as a result of possibility of cross contamination between the birds inoculated with the two recombinant organisms. It is also clear from the results that, at least under the conditions selected for the electroporation, the use of the acridine orange label increases significantly the efficiency of the transfer of the donor DNA to the recipient host. The average lesion scores of 1.5 and 1.2 and the degree of protection with 6 out of 7 birds having significantly reduced lesions are similar to results that are normally observed upon challenge of birds inoculated with native E. tenella in traditional immunization programs.
The above example clearly demonstrates the ability of the recombinant coccidia in the present invention to confer immunity in an animal host against infection by the coccidium which acts as a donor organism. ' While the example has only utilized whole DNA from one species it would be readily apparent to those of skill in the art that the invention could be practiced utilizing more than one species as a donor organism thereby conferring immunity to multiple specie of coccidia in an animal host. Also as the understanding of coccidial antigenic determinants and the immunity evoked in the host animal by immunization with a coccidia vaccine increases in W 25 ~~~~~?r~~~
the future the invention may be utilized to take advantage of this increased knowledge. For example, as significant antigens and the genes encoding them are identified, such genes may be isolated and packaged in accordance with the present invention to permit the expression of the gene and production of the antigenic determinant in the recombinant coccidium. Such genes could include genes from many species of coccidia thereby conferring immunity to a multitude of species through the use of the recombinant coccidium of the present invention.
The recombinant coccidia of the present invention permits the development of novel vaccines which induce immunity to more pathogenic species of coccidia by incorporating the DNA from such species into less pathogenic species. Such a vaccine has a major impact on the concept of coccidial vaccine manufacturing. The vaccine will be used with less impunity than present live vaccines and the industry now has a viable and longer-lasting alternative to medication. By utilizing a less pathogenic species of coccidia as the recipient, the potential for accidentally inducing disease in a flock through misadministration of the vaccine is greatly reduced.
Vaccine doses can be increased relative to traditional vaccines to ensure that even if individual chicks receive reduced doses, there will be sufficient antigen present to confer immunity. Unlike present live vaccines, the vaccine of the present invention does not require anticoccidials either in the feed or the water to assist in control of coccidiosis.
Although various preferred embodiments of the present invention have been described herein in detail, it will be appreciated by 'those skilled in the art, that variations may be made thereto without departing from the spirit of the invention or the scope of the appended claims.
t~B~~~'~~~~
BIBLIOGRAPHY
Bhogal, Balbir S.et al (1987), "Generation and Functional characterization of Eimeria Tenella immune chicken T-cell clones", Avian Imm, pages 127-144.
Bhogal, B.S.et al (1992), "Potential of a recombinant antigen as a prophylactic vaccine for day-old broiler chickens agains Eimeria acervuline and Eimeria tenella infections", Veterinary Immunology and immunopathology, ~.2,: 323, 335 .
Brothers, Virginia M. et al (1988), "Characterization of a surface antigen of Eimeria tenella sporozoites and synthesis from a cloned cDrIA in Escherichia coli", Mol Biochem Parasitology 2$: 235-248.
Castle, Marc D. et al (1991), "Characterization of a Recombinant Eimeria acervulina antigen expressed in sporozoite and merozoite developmental stages" J.
Parasitology 2Z: 384-390.
Clarke, Lorraine E.et al (1987), "Isolation of a _ amp3 genomic recombinants coding for antigens of Eimeria tenella", Mol. Biochem Parasitology ,2~: 79-87.
Danforth, H.D.(1986), "Use of Hybridoma Antibodies combined with genetic engineering in the study of protozoan parasites: A review", in McDougall et al (1986).
Hein, Helen E.(1976), "Eimeria ~cervulina, E. brunetti, E.
maxima, and E. necatrix: Low Doses of Oocysts to Immunize Young Chickens",Exp Parasitology 4Q: 250-260.
Jenkins, Mark C. (1988), "Eimeria acervulina: DNA Cloning and Characterization of Recombinant Sporozoite and Merozoite Antigens", Exp Parasiltology .~.~: 96-107) Lillehoj, Hyun S. et al (1988), "Eimeria acervulina:
Evaluation of the Cellular and Antibody Responses to the Recombinant Coccidial Antigens in B-Congenic Chickens", Exp Parasitologyu .~Z: 148-158.
Long, Peter L.(1990), "Coccidiosis of Man and Domestic Animal", CRC Pres Inc.
McDougall, Larry R.et al (1986), "Research in Avian Coccidia", University of Georgia.
Murray, Keith P. et al (1986), "Eimeria tenella - In vivo immunization studies with sporozoite antigen", in McDougall et al (1986).
Profous-Juchelka, Helen et al (1988), "Identification and characterization of cDNA clones encoding antigens of Eimeria tenella", Mol Biochem Parasitology ,~Q: 233-242.
Wisher, Martin H. (1986), "Identification of the sporozoite antigens of Eimeria tenella" Mol. Biocem Parasitology ~: 7-15.
Wong, R.B., and Thammana P. (1986), "Monoclonal Antibody Defined Stage Specific And Stage Independent Antigens of Eimeria tenella",
Claims (16)
1. A recombinant coccidium comprising a relatively non-pathogenic strain of Eimeria as a recipient host containing DNA from one or more donor coccidia selected from other strains or species of Eimeria wherein the recombinant coccidium expresses surface antigenic determinants encoded by the DNA of the donor organism.
2. A recombinant coccidium as claimed in Claim 1, wherein the host coccidium is E. acervulina.
3. A recombinant coccidia as claimed in Claim 2, wherein the donor coccidium is selected from one or more of E. tenella, E, neaotrix, E.
brunetti and E. maxima.
brunetti and E. maxima.
4. A recombinant coccidia as claimed in Claim 3, wherein the donor coccidia is E. tenella.
5. A method of producing a recombinant coccidium comprising:
(a) extracting DNA from a donor strain or species of Eimeria, and (b) introducing the extracted donor DNA into a recipient host strain or species of Eimeria in a manner to permit expression of the donor DNA in the host coccidium.
(a) extracting DNA from a donor strain or species of Eimeria, and (b) introducing the extracted donor DNA into a recipient host strain or species of Eimeria in a manner to permit expression of the donor DNA in the host coccidium.
6. A method as claimed in Claim 5, wherein the donor DNA is packaged into a vector containing telomere DNA sequences.
7. A method as claimed in Claim 6, wherein the vector functions as a yeast artificial chromosome (YAC).
8. A method as claimed in Claim 7, wherein the YAC is pYAC-RC.
9. A method as claimed in Claim 5, wherein the donor DNA is introduced into the recipient host coccidia by electroporation, microinjection or incubation in high ionic strength buffer.
10. A method as claimed in Claim 9, wherein the donor DNA is introduced into the recipient host coccidia by electroporation.
11. A recombinant coccidiosis vaccine comprising a relatively non-pathagenic recipient host of Eimeria to which has been introduced sufficient DNA from one or more coccidia selected from donor other strains or species of Eimeria to produce immunity to the recipient and donor strains in a host animal through inoculation of the host animal by the recombinant coccidia.
12. A recombinant coccidiosis vaccine as claimed in Claim 11, wherein the host coccidia is E, acervulina.
13. A recombinant coccidiosis vaccine as claimed in Claim 12, wherein the donor coccidia is selected from one or more of E. tenella, E. necatrix, E.
brunetti and E. maxima.
brunetti and E. maxima.
14. A recombinant coccidiosis vaccine as claimed in Claim 13, wherein the donor coccidia is E. tenella.
15. A recombinant coccidiosis vaccine according to any one of Claims 11 to 14, wherein the recombinant coccidia is diluted in an aqueous edible gum solution which results in uniform suspension of said coccidia.
16. The use of a recombinant coccidiosis vaccine comprising a relatively non-pathagenic recipient strain of Eimeria to which has been introduced sufficient DNA from one or more coccidia selected from donor other strains or species of Eimeria to produce immunity to the recipient and donor strains in a host animal through inoculation of the host animal by the recombinant coccidia for immunizing an animal against infection by coccidia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002098773A CA2098773C (en) | 1993-06-18 | 1993-06-18 | Recombinant coccidia and its use in a vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002098773A CA2098773C (en) | 1993-06-18 | 1993-06-18 | Recombinant coccidia and its use in a vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2098773A1 CA2098773A1 (en) | 1994-12-19 |
CA2098773C true CA2098773C (en) | 1999-09-21 |
Family
ID=4151815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002098773A Expired - Lifetime CA2098773C (en) | 1993-06-18 | 1993-06-18 | Recombinant coccidia and its use in a vaccine |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2098773C (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT831897E (en) | 1995-06-07 | 2001-07-31 | Pfizer | INVOIC VACCINATION AGAINST COCCIDIOSIS |
WO1996040233A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | In ovo vaccination against coccidiosis |
CA2213385A1 (en) * | 1997-08-20 | 1999-02-20 | Eng-Hong Lee | Method of protecting against coccidiosis infections in poultry |
US6627205B2 (en) | 1997-12-01 | 2003-09-30 | Pfizer Incorporated | Ovo vaccination against coccidiosis |
US6984378B1 (en) | 1999-02-26 | 2006-01-10 | Pfizer, Inc. | Method for the purification, recovery, and sporulation of cysts and oocysts |
WO2003020917A1 (en) | 2001-08-30 | 2003-03-13 | Embrex, Inc. | Improved methods for producing oocysts |
US11000580B2 (en) | 2010-12-27 | 2021-05-11 | Eng Hong Lee | Roadmap for controlling malaria |
-
1993
- 1993-06-18 CA CA002098773A patent/CA2098773C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2098773A1 (en) | 1994-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tsuboi et al. | Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein | |
Chapman et al. | The Houghton strain of Eimeria tenella: a review of the type strain selected for genome sequencing | |
EP0374869A1 (en) | Recombinant DNA molecules and their method of production | |
EP0716697B1 (en) | DIFFERENTIALLY EXPRESSED $i(LEISHMANIA) GENES AND PROTEINS | |
JPH06225786A (en) | Expression of plasmodium falciparum polypeptide from cloned cdna | |
WO1986000528A1 (en) | Cloned gene and method for making and using the same | |
Scheiblhofer et al. | Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP‐specific Th2 type immune responses and improvesprotection against malaria infection | |
CA2098773C (en) | Recombinant coccidia and its use in a vaccine | |
EP0172865B2 (en) | Dna sequences, recombinant dna and processes for producing antigens of plasmodium falciparum | |
EP1756149B1 (en) | Live, oral vaccine for protection against shigella dysenteriae serotype 1 | |
CA2498604A1 (en) | Live antenuated parasite vaccine | |
AU621903B2 (en) | Coccidiosis vaccine | |
KR100197455B1 (en) | Recombinant coccidiosis vaccine-5-7 eimeria surface antigen | |
KR100244828B1 (en) | Coccidiosis vaccines | |
WO1994024291A2 (en) | Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation | |
WO1988002757A1 (en) | Hybrid proteins or polypeptides | |
DE68909041T2 (en) | Eimeria tenella vaccine. | |
JPH06500990A (en) | new protein | |
Qu et al. | CRISPR-Cas9-based method for isolating microgametes of Eimeria tenella | |
Shirley et al. | Integrating genetics and genomics to identify new leads for the control of Eimeria spp. | |
DE60319741T2 (en) | INCLUSIVE BODY FOR ORAL VACCINATION OF ANIMALS | |
CN114181938B (en) | Recombinant coccidian vector for expressing R7 protein and fluorescent label and detection method thereof | |
CN113318223B (en) | Classical swine fever virus and porcine epidemic diarrhea virus subunit combined vaccine and preparation method thereof | |
CN113372453B (en) | Fusion protein and porcine epidemic diarrhea virus S1 protein recombinant subunit vaccine | |
US20100093062A1 (en) | Transfection system for perkinsus species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |